Recent applications of computational methods to allosteric drug discovery

被引:13
作者
Govindaraj, Rajiv Gandhi [1 ]
Thangapandian, Sundar [1 ]
Schauperl, Michael [1 ]
Denny, Rajiah Aldrin [2 ]
Diller, David J. [1 ]
机构
[1] HotSpot Therapeut Inc, Computat Chem, Boston, MA 02210 USA
[2] Medizen Inc, Canton, MA USA
关键词
allostery; computational modeling; molecular dynamics; structure-based design; fragment-based screening; MOLECULAR-DYNAMICS; CATHEPSIN-K; CANCER PROGRESSION; CRYSTAL-STRUCTURE; NUCLEAR RECEPTOR; PROCATHEPSIN B; BINDING; PTP1B; INHIBITORS; KINASE;
D O I
10.3389/fmolb.2022.1070328
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Interest in exploiting allosteric sites for the development of new therapeutics has grown considerably over the last two decades. The chief driving force behind the interest in allostery for drug discovery stems from the fact that in comparison to orthosteric sites, allosteric sites are less conserved across a protein family, thereby offering greater opportunity for selectivity and ultimately tolerability. While there is significant overlap between structure-based drug design for orthosteric and allosteric sites, allosteric sites offer additional challenges mostly involving the need to better understand protein flexibility and its relationship to protein function. Here we examine the extent to which structure-based drug design is impacting allosteric drug design by highlighting several targets across a variety of target classes.
引用
收藏
页数:22
相关论文
共 129 条
[1]   MEK and the inhibitors: from bench to bedside [J].
Akinleye, Akintunde ;
Furqan, Muhammad ;
Mukhi, Nikhil ;
Ravella, Pavan ;
Liu, Delong .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
[2]   In silico Guided Drug Repurposing: Discovery of New Competitive and Non-competitive Inhibitors of Falcipain-2 [J].
Alberca, Lucas N. ;
Chuguransky, Sara R. ;
Alvarez, Cora L. ;
Talevi, Alan ;
Salas-Sarduy, Emir .
FRONTIERS IN CHEMISTRY, 2019, 7
[3]   PD-098059 IS A SPECIFIC INHIBITOR OF THE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE IN-VITRO AND IN-VIVO [J].
ALESSI, DR ;
CUENDA, A ;
COHEN, P ;
DUDLEY, DT ;
SALTIEL, AR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (46) :27489-27494
[4]   DOCK 6: Impact of New Features and Current Docking Performance [J].
Allen, William J. ;
Balius, Trent E. ;
Mukherjee, Sudipto ;
Brozell, Scott R. ;
Moustakas, Demetri T. ;
Lang, P. Therese ;
Case, David A. ;
Kuntz, Irwin D. ;
Rizzo, Robert C. .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 2015, 36 (15) :1132-1156
[5]   Druggability Assessment of Allosteric Proteins by Dynamics Simulations in the Presence of Probe Molecules [J].
Bakan, Ahmet ;
Nevins, Neysa ;
Lakdawala, Ami S. ;
Bahar, Ivet .
JOURNAL OF CHEMICAL THEORY AND COMPUTATION, 2012, 8 (07) :2435-2447
[6]   Protein Arginine Methylation in Mammals: Who, What, and Why [J].
Bedford, Mark T. ;
Clarke, Steven G. .
MOLECULAR CELL, 2009, 33 (01) :1-13
[7]   Cathepsin L, transmembrane peptidase/serine subfamily member 2/4, and other host proteases in COVID-19 pathogenesis - with impact on gastrointestinal tract [J].
Berdowska, Izabela ;
Matusiewicz, Malgorzata .
WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (39) :6590-6600
[8]   Molecular dynamics simulation study of PTP1B with allosteric inhibitor and its application in receptor based pharmacophore modeling [J].
Bharatham, Kavitha ;
Bharatham, Nagakumar ;
Kwon, Yong Jung ;
Lee, Keun Woo .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2008, 22 (12) :925-933
[9]   Asymmetric Dimethylarginine (ADMA): A Promising Biomarker for Cardiovascular Disease? [J].
Bouras, Georgios ;
Deftereos, Spyridon ;
Tousoulis, Dimitrios ;
Giannopoulos, Georgios ;
Chatzis, Georgios ;
Tsounis, Dimitrios ;
Cleman, Michael W. ;
Stefanadis, Christodoulos .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2013, 13 (02) :180-200
[10]   Equilibrium fluctuations of a single folded protein reveal a multitude of potential cryptic allosteric sites [J].
Bowman, Gregory R. ;
Geissler, Phillip L. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (29) :11681-11686